Teneobio, Inc.   Report issue

For profit Phase 1
Founded: Newark CA United States (2009)
Status: Acquired by Amgen (2021)

Organization Overview

First Clinical Trial
2019
NCT03933735
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Teneobio, Inc. | TeneoOne Inc. | TeneoTwo Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 6
  • # of Trial APIs: 9